[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Minoryx Therapeutics, S.L.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100502254","phase-3-a-clinical-study-to-assess-the-efficacy-and-safety-of-leriglitazone-in-adult-male-subjects-with-cerebral-adrenoleukodystrophy-100502254",false,"NCT05819866","A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy","CALYX","Key Inclusion Criteria:\n\n* Subject is male and aged ≥18 years.\n* Subject has progressive cALD, defined as GdE+ brain lesions.\n* Subjects for whom HSCT is not recommended by the investigator or subject is not willing to undergo HSCT.\n* Subject has a Loes score ≥0.5 and ≤12 at Screening.\n* Subject does not have major functional disability in the Major Functional Disabilities-Neurological Function Score (MFD-NFS), except for \"wheelchair bound\" or \"total incontinence\", which will be allowed as these are considered expected symptoms of AMN in the time course of the disease\n* Subject does not have major cognitive impairment which would impair his ability to take part in the study as determined by the investigator at screening.\n\nKey Exclusion Criteria:\n\n* Subject who had previous bone marrow transplantation (HSCT) or treatment with ex-vivo gene therapy (eli-Cel).\n* Subject has known type 1 or type 2 diabetes.\n* Subject has known hypersensitivity or intolerance to pioglitazone or any other thiazolidinedione.\n* Subject is taking or has taken honokiol, pioglitazone, or other thiazolidinediones within 3 months prior to Screening.\n* Subject with current participation in another interventional clinical study or within 1 month prior to Screening.\n* Subject with other medical, neuropsychiatric or social conditions that, in the opinion of the investigator, are likely to adversely affect the risk-benefit of study participation, interfere with study compliance, or confound the study results.","MALE","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.",[26],"Cerebral Adrenoleukodystrophy (cALD)","RECRUITING","2025-11-14",{"date":30,"type":31},"2025-11-17","ACTUAL",{"date":33,"type":31},"2023-07-12",{"date":35,"type":20},"2027-05",{"name":37,"class":38},"Minoryx Therapeutics, S.L.","INDUSTRY",13,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100529772","disease-progression-in-women-with-x-linked-adrenoleukodystrophy-100529772","NCT06178120","Disease Progression in Women With X-linked Adrenoleukodystrophy","An Observational Study to Assess Disease Progression in Women With X-linked Adrenoleukodystrophy","Inclusion Criteria:\n\n1. Women aged 18 years old or older.\n2. Diagnosis of X-linked ALD based on genetic testing, altered VLCFA levels, or family history.\n3. Willing to undergo annual follow-up visits, including brain and spinal cord MRI scans.\n4. Provision of written informed consent.\n5. Affiliation or beneficiary of a French social security system or of such a regime.\n\nExclusion Criteria:\n\n1. Any condition that in the opinion of the investigator are likely to adversely affect the study participation, interfere with study compliance, or confound the study results.\n2. Under treatment or previous treatment with leriglitazone.\n3. Pregnant or lactating women.\n4. Subjects benefiting from laws aimed at protecting vulnerable adults: subjects being deprived of liberty by judicial or administrative decision, subjects under guardianship.\n5. Participation in an interventional clinical trial.","FEMALE",{"count":19,"type":20},"OBSERVATIONAL","Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.",[52],"X-linked Adrenoleukodystrophy","2024-01-29",{"date":55,"type":31},"2024-01-31",{"date":57,"type":31},"2024-01-02",{"date":59,"type":20},"2027-06",{"name":37,"class":38},1,""]